Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire for more information on oral cancer
Vigilant Biosciences, Inc. today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC).The studies, along with others, helped provide direction for the clinical application of Vigilant Biosciences OncAlert®Oral Cancer and OncAlert Labs product lines as well as pipeline programs under development. The abstracts will be presented at multiple conferences in the U.S. and abroad throughout March and April 2017.
Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, will showcase its OncAlert® Oral Cancer product line in Hall 5.1, Stand: D069 at the 37th International Dental Show (IDS), the world’s leading tradeshow for the dental industry, being held March 21-25, 2017 in Cologne, Germany.
Matthew H.J. Kim, Founder, Chairman and CEO at Vigilant Biosciences, will present a poster on the study, “Multivariate oral rinse models predict Head and Neck squamous cell carcinoma (HNSCC),” at the 6th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO), from March 16-18, 2017, in Barcelona, Spain.
Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer at Vigilant Biosciences, will present at two upcoming conferences in San Francisco: the BioLink 2017 China Healthcare Industry Investment and Licensing Conference, taking place January 8, 2017 at the San Francisco Hilton Airport Hotel, and Medtech Showcase 2017 (at Biotech Showcase™), taking place at the Parc 55 San Francisco, January 10 – 11, 2017.
Vigilant Biosciences today announced exclusive multi-year distribution agreement for sales and marketing of its OncAlert® Oral Cancer product line in Spain, Portugal and Germany.
The Company made the announcement in conjunction with the MEDICA Trade Fair, where the Company is showcasing its OncAlert Oral Cancer product line in Hall 16, booth #D04.
Company to deliver oral presentation of data related to studies conducted to better understand the relationship between CD44, EGFR and p16 expression in oral cavity and oropharyngeal cancers, and whether particular patterns of CD44, EGFR and p16 staining are associated with overall and progression-free survival.
The study, titled, “Multivariate models which include oral rinse CD44 and total protein levels combined with clinical variables accurately predicts head and neck squamous cell carcinoma,” was based on previous proof-of-concept studies conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, which demonstrated the ability to identify the presence of the tumor-initiating and stem cell-associated biomarker CD44, together with total protein, to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms, by using a simple, oral rinse procedure.
Company to give presentation of data related to proof-of-concept studies by Sylvester Comprehensive Cancer Center (“Sylvester”) at the University of Miami Miller School of Medicine, titled CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at American Head and Neck Society (AHNS) 9th International Conference on Head and Neck Cancer.
Today Vigilant Biosciences announced the successful completion of a $5 million round of financing through its Series B2 offering, bringing the total Series B financing raise to $10.5 million and the total amount of funding raised to date to $12.5 million.
First Quantitative Laboratory Developed Test to Accurately Measure a Tumor-Initiating and Stem Cell Associated Biomarker for Head and Neck Cancer in an Oral Rinse